VRC Medical Services, a women-owned specialty pharmaceutical distribution company supporting clinical research, announced the launch of a dedicated comparator support program designed to help ...
The FDA declined to review Moderna's mRNA influenza vaccine due to inadequate clinical trial comparators for older adults.
Derbyshire Times on MSN
"I cannot put into words how angry I feel. We want clear answers": Nurses disappointed as full financial review at Ashgate Hospice not going ahead
Ashgate nurses are calling for clear answers as to why frontline inpatient services were impacted to such a degree after redundancies affecting 33 roles at the Chesterfield hospice.
In the modern boardroom, the term “happiness” used to be dismissed as a soft, nebulous concept – something for the breakroom, ...
Recent US drug pricing reforms adopt international prices shaped by quality-adjusted life-year (QALY)-based assessments, despite longstanding federal prohibitions on using QALYs in coverage and ...
Quality inspection at a plastic molding company starts with measurement tools that would look at home in a science lab. Coordinate measuring machines, optical comparators, and laser micrometers are ...
Center for Biologics Evaluation and Research (CBER) issued Moderna a refusal-to-file letter for its mRNA influenza vaccine, mRNA-1010. Two weeks later, under mounting pressure from the scientific ...
Opinion
I was a Moderna exec when the Covid vaccine rolled out. That spirit of possibility is no more
The pharmaceutical industry is not the enemy,” writes Richard Hughes IV, who was Moderna’s VP for public policy when the Covid vaccine rolled out.
Climb Bio (NASDAQ:CLYM) outlined a slate of near-term clinical milestones and its broader autoimmune disease strategy during ...
Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 3:15 PM ESTCompany ParticipantsJean-Charles Soria - Senior Vice ...
Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 1:00 PM ESTCompany ParticipantsJoshua Bleharski - ...
Morning Overview on MSN
New mRNA flu shot proves 30%+ more powerful at stopping influenza A
Moderna says its experimental mRNA influenza vaccine, mRNA-1010, showed more than 30% greater relative vaccine efficacy against influenza A than a licensed egg-based flu shot in a large Phase 3 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results